Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

(NY: VTAK )

0.4187 -0.0013 (-0.31%)
Official Closing Price Updated: 8:00 PM EST, Nov 27, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about VTAK

< Previous 1 2 3 4 Next >
Catheter Precision, Inc. Announces Initial LockeT Purchase From Montefiore Medical Center
Via ACCESSWIRE
Catheter Precision, Inc. Announces Third Quarter Update and Financial Results
Via ACCESSWIRE
Catheter Precision, Inc. Announces New Clinical Data Presented at SCRN
Via ACCESSWIRE
Catheter Precision, Inc. Announces Exercise of Warrants for $4.9 Million of Gross Proceeds
Via ACCESSWIRE
Catheter Precision to Attend Society for Cardiac Robotic Navigation With New Clinical Data Presented on October 28 – 29
Via ACCESSWIRE
Catheter Precision, Inc. (NYSE American: VTAK) Reports Preliminary Unaudited Revenue for the Second Quarter and Six Months Ended June 30, 2024
Via ACCESSWIRE
Catheter Precision Announces Clinical Publication of Non-Invasive Stereotactic Radioablation Using VIVO
Via ACCESSWIRE
Catheter Precision to Attend the International Symposium on Catheter Ablation Techniques
Via ACCESSWIRE
Catheter Precision Scheduled to Attend the International Ventricular Tachycardia (VT) Symposium October 11 - 12 in New York City
Via ACCESSWIRE
Catheter Precision Continues to Expand Clinical Data and Acceptance of VIVO
Via ACCESSWIRE
Catheter Precision, Inc. Receives Chinese Patent for LockeT
Via ACCESSWIRE
Catheter Precision, Inc. Expands LockeT Distribution to Middle East
Via ACCESSWIRE
Catheter Precision, Inc. (NYSE American: VTAK) Reports First Purchase Order for LockeT in the Pacific Northwest Territory
Via ACCESSWIRE
Presentation at European Society of Cardiology Demonstrates VIVO Accuracy in Complex VT Patients
Via ACCESSWIRE
Catheter Precision, Inc. (NYSE American:VTAK) Reports First Purchase Order for LockeT in a New US Territory
Via ACCESSWIRE
Catheter Precision, Inc. Announces Closing of $3.6 Million Underwritten Public Offering and Exercise of Overallotment Option
Via ACCESSWIRE
Catheter Precision, Inc. Announces Pricing of $3.1 Million Underwritten Public Offering
Via ACCESSWIRE
Catheter Precision, Inc. (NYSE American: VTAK) Reports Q2 2024 Highlights and Operational Performance Report
Via ACCESSWIRE
Catheter Precision, Inc. Announces Publication of LockeT Data in the Journal of Cardiovascular Electrophysiology
Via ACCESSWIRE
LargeCap Big Tech Stocks Report Earnings Today: Discover SmallCap Stocks Inside to Watch Now!
Via AB Newswire
Catheter Precision, Inc. Completes Enrollment of 75 Patients in LockeT-II Study
Via ACCESSWIRE
5 Stocks in the News to Watch Now: LGVN, PRSO, SIRI, INBS, VTAK
Via AB Newswire
Exposures Product Safety
Catheter Precision Inc. (NYSE American: VTAK) Moves Forward with Aggressive Expansion Strategy and New Share Structure
Via AB Newswire
Catheter Precision, Inc. Announces the Completion of Patient Follow-up for the VIVO European Registry and New Product Evaluations of VIVO
Via ACCESSWIRE
Catheter Precision, Inc. Announces Effectiveness of 1-for-10 Reverse Stock Split
Via ACCESSWIRE
Major Potential: 5 NASDAQ / NYSE Stocks Under $1 SGMO, FTCI, VTAK, SPRB, DNA
Via AB Newswire
Roaring Kitty Expands Horizons: Key Stocks to Watch as Influencer Shakes Up Market: CHWY, DYAI, WOOF, VTAK, INBS
Via AB Newswire
July 2024 Hot Small-Cap Stocks Under $5 Gaining Now: KAVL, VTAK, INBS, BSFC, PRSO
Via AB Newswire
Catheter Precision Inc. (NYSE American: VTAK) Stock Volume Soars with Middle East Expansion of VIVO 3D Heart Imaging System
Via AB Newswire
Catheter Precision, Inc. Announces Receipt of First Purchase Order for VIVO from Distributor in Middle East
Via ACCESSWIRE
< Previous 1 2 3 4 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.